NervGen Pharma Statistics

Total Valuation

NervGen Pharma has a market cap or net worth of CAD 282.54 million. The enterprise value is 268.15 million.

Market Cap	282.54M
Enterprise Value	268.15M

Important Dates

The last earnings date was Wednesday, May 14, 2025.

Earnings Date	May 14, 2025
Ex-Dividend Date	n/a

Share Statistics

NervGen Pharma has 72.45 million shares outstanding. The number of shares has increased by 17.34% in one year.

Current Share Class	72.45M
Shares Outstanding	72.45M
Shares Change (YoY)	+17.34%
Shares Change (QoQ)	+0.97%
Owned by Insiders (%)	2.57%
Owned by Institutions (%)	3.97%
Float	60.58M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	203.34
P/TBV Ratio	301.06
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-10.47
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.06, with a Debt / Equity ratio of 0.06.

Current Ratio	1.06
Quick Ratio	1.03
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -253.35% and return on invested capital (ROIC) is -158.74%.

Return on Equity (ROE)	-253.35%
Return on Assets (ROA)	-68.24%
Return on Invested Capital (ROIC)	-158.74%
Return on Capital Employed (ROCE)	-1,871.04%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +65.25% in the last 52 weeks. The beta is 0.60, so NervGen Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.60
52-Week Price Change	+65.25%
50-Day Moving Average	3.66
200-Day Moving Average	2.95
Relative Strength Index (RSI)	49.34
Average Volume (20 Days)	369,522

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-26.00M
Pretax Income	-25.61M
Net Income	-25.61M
EBITDA	-25.96M
EBIT	-26.00M
Earnings Per Share (EPS)	-0.37

Full Income Statement

Balance Sheet

The company has 14.47 million in cash and 81,838 in debt, giving a net cash position of 14.39 million or 0.20 per share.

Cash & Cash Equivalents	14.47M
Total Debt	81,838
Net Cash	14.39M
Net Cash Per Share	0.20
Equity (Book Value)	1.39M
Book Value Per Share	0.02
Working Capital	938,468

Full Balance Sheet

Cash Flow

Operating Cash Flow	-17.71M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NervGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.34%
Shareholder Yield	n/a
Earnings Yield	-9.06%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1